Following decades of cumulative efforts, a number of infectious disease tests and technologies broke new ground in 2025, hinting at rapid advances in the development of new systems and assays. But the past year also saw its fair share of upheaval, possibly suggesting more may be in store in 2026.

Chinese molecular diagnostics and precision medicine firm GenePlus Technology said on Sunday that it has filed for an initial public offering on the Hong Kong Stock Exchange.

Molecular diagnostics firm BillionToOne reported after the close of the market on Tuesday that its Q3 2025 revenues more than doubled year over year.

The Global Health Innovative Technology (GHIT) Fund said Monday that it has invested ¥70 million ($460,000) in the development of a prototype molecular assay to detect mpox.

Paradigm Health announced last Thursday that it acquired Flatiron Health's clinical research business, establishing a multiyear collaboration between the two companies.

Swedish diagnostics firm Devyser said Thursday that its next-generation sequencing-based test for stem cell transplantation monitoring has received regulatory approval in Canada.

Scout Health announced Wednesday that it has been awarded up to $6 million in funding support from the antimicrobial resistance nonprofit CARB-X. The firm plans to use the funding to finalize development of a next-generation version of its rapid point-of-care system and assay for chlamydia and gonorrhea and hopes to soon begin pilot studies in low- and middle-income countries (LMICs).

As part of its strategic expansion into precision dermatology, Castle Biosciences recently introduced a new assay to guide systemic treatment decision making for the immune-driven disease atopic dermatitis. Castle expects to expand the limited launch of its AdvanceAD-Tx test over the next year to pursue a total addressable market that it estimates to be as much as $33 billion.

Diagnostics firm IdentifySensors Biologics has recently demonstrated proof of concept for the use of its electrochemical sensor-based diagnostic platform Check4 for cancer testing and is now moving closer to commercialization of the platform and related tests.

JP Morgan, BTIG, and Jefferies announced separately Monday that they have initiated coverage of molecular diagnostics firm BillionToOne.